目的:探索稳定期COPD患者实施4S卧位康复操的治疗效果。方法:纳入2023年6月至2024年6月玉环市第二人民医院健共体集团医院收治的稳定期COPD患者,按照随机数字表法将其分为对照组51例和研究组49例,对照组予以常规肺康复方案治疗,研究组在对照组基础加以4S卧位康复操干预,并分析2组干预后的治疗效果。结果:在常规肺康复方案基础上加以实施4S卧位康复操6月后,结果提示,相比常规肺康复干预措施组(对照组),常规肺康复方案 + 4S卧位康复操组(研究组)的6MWT以及mMRC评分显著升高,CAT评分显著下降,差异具有统计学差异(P Objective: To explore the therapeutic effect of 4S lying position rehabilitation exercise in stable COPD patients. Methods: From June 2023 to June 2024, stable COPD patients admitted to the Health Community Group Hospital of the Second People’s Hospital of Yuhuan City were divided into control group (51 cases) and study group (49 cases) according to random number table method. The control group was given routine pulmonary rehabilitation treatment. The study group was treated with 4S recumbent rehabilitation exercise on the basis of the control group, and the therapeutic effect of the intervention was analyzed. Results: After 6 months of implementation of 4S lying position rehabilitation exercise on the basis of conventional pulmonary rehabilitation program, the results indicated that compared with conventional pulmonary rehabilitation intervention group (control group), the 6MWT and mMRC scores of conventional pulmonary rehabilitation program + 4S lying position rehabilitation exercise group (study group) were significantly increased, and the CAT scores were significantly decreased, with statistical difference (P < 0.05). Conclusion: On the basis of routine pulmonary rehabilitation treatment, 4S lying position rehabilitation exercise can not only significantly alleviate the severity of respiratory fatigue, but also enhance the exercise ability and
目的通过网状Meta分析系统评价三联吸入型药物治疗稳定期慢性阻塞性肺疾病(COPD)的有效性和安全性。方法计算机检索万方数据知识服务平台、中国知网、维普网、PubMed、Embase、Cochrane Librany、Web of Science公开发表的三联制剂或二联制剂治疗稳定期COPD有效性和安全性的研究,检索时限自建库至2024年7月。由两名研究人员按照文献纳入与排除标准独立筛选文献、提取资料并进行文献偏倚风险评估。绘制累积排序概率图并计算累积排序概率图下面积(SUCRA),绘制漏斗图以判断纳入文献是否存在发表偏倚。结果最终纳入随机对照试验12篇,共包含25562例患者,其中试验组10378例、对照组15184例。贝叶斯网状Meta分析结果显示:接受布地奈德/格隆溴铵/福莫特罗(以下简称BGF)治疗者第1秒用力呼气容积(FEV1)相对基线变化值大于接受格隆溴铵/福莫特罗(以下简称GFF)、布地奈德/福莫特罗干粉吸入剂(以下简称BUD/FORM)、布地奈德/福莫特罗气雾剂(以下简称BFF)治疗者(P<0.05)。接受倍氯米松/福莫特罗/格隆溴铵(以下简称BDP/FF/G)治疗者中重度急性加重发生率低于接受BGF、氟替卡松/乌美溴铵/维兰特罗(以下简称FF/UMEC/VI)及二联制剂〔倍氯米松/福莫特罗(以下简称BDP/FF)除外〕治疗者(P<0.05);接受BGF治疗者中重度急性加重发生率低于接受BFF、GFF治疗者(P<0.05);接受FF/UMEC/VI治疗者中重度急性加重发生率低于接受氟替卡松/维兰特罗(以下简称FF/VI)、BUD/FORM、乌美溴铵/维兰特罗(以下简称UMEC/VI)治疗者(P<0.05)。接受BGF治疗者肺炎发生率高于接受GFF治疗者(P<0.05);接受FF/UMEC/VI治疗者肺炎发生率高于接受BUD/FORM、UMEC/VI治疗者(P<0.05)。累计排序概率图分析结果显示,接受三联制剂治疗者FEV1相对基线变化值的SUCRA最大为BGF(99.8%),中重度急性加重发生率的SUCRA最大为BDP/FF/G(98.8%),肺炎发生率的SUCRA最大为BDP/